Stock Analysis
- Hong Kong
- /
- Healthcare Services
- /
- SEHK:9955
ClouDr Group First Half 2024 Earnings: CN¥0.20 loss per share (vs CN¥0.29 loss in 1H 2023)
ClouDr Group (HKG:9955) First Half 2024 Results
Key Financial Results
- Revenue: CN¥2.12b (up 18% from 1H 2023).
- Net loss: CN¥115.8m (loss narrowed by 26% from 1H 2023).
- CN¥0.20 loss per share (improved from CN¥0.29 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ClouDr Group Earnings Insights
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare industry in Hong Kong.
Performance of the Hong Kong Healthcare industry.
The company's shares are down 16% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for ClouDr Group you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:9955
ClouDr Group
An investment holding company, provides supplies and software as a service (SaaS) to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for patients with chronic condition management.